We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus‐infected children in relation to treatment outcomes.
- Authors
Archary, Moherndran; Mcllleron, Helen; Bobat, Raziya; LaRussa, Philip; Sibaya, Thobekile; Wiesner, Lubbe; Hennig, Stefanie
- Abstract
Aims: Describe the pharmacokinetics (PK) of the antiretroviral drugs abacavir and lamivudine in malnourished paediatric patients and relate to viral load outcomes after 12 and 48 weeks of treatment. Methods: Severely malnourished human immunodeficiency virus‐infected children were randomized to early (within 14 days) or delayed (after nutritional recovery) initiation of antiretroviral treatment (ART) using World Health Organization weight‐band dosages. Abacavir and lamivudine concentrations were measured as a secondary objective on day 1 and day 14 and patients were followed‐up to week 48. Population PK of abacavir and lamivudine were described using NONMEM. Results: In total, 623 abacavir and 627 lamivudine concentrations were collected from 75 paediatric patients aged 0.1–10.8 (median 1.4) years. Abacavir PK was described by a 2‐compartment model, patients randomized to early ART showed increased bioavailability of 31%. Apparent clearance (CL/F, L/h/7 kg) of abacavir increased from day 1 to day 14 from 3.33 (95% confidence interval 2.71–4.12) to 5.86 (95% confidence interval 4.78–7.3). A 1‐compartment model described lamivudine PK, variability on CL/F was explained by maturation with age, with age at half‐matured CL/F being 4 months. For both drugs allometrically scaled total body weight was related to CL/F and apparent volume of distribution. PK exposure did not correlate with virological outcomes or death at 12 or 48 weeks. Conclusion: Increases in Abacavir's CL/F between day 1 to day 14, bioavailability and PK variability with early start of ART was found in this cohort of severely malnourished children; however, these changes did not influence virological outcomes. The study supports the use of weight‐band dosage tables.
- Subjects
WORLD Health Organization; HIV-positive children; LAMIVUDINE; ABACAVIR; TREATMENT effectiveness; PHARMACOKINETICS; ANTIRETROVIRAL agents; HIV
- Publication
British Journal of Clinical Pharmacology, 2019, Vol 85, Issue 9, p2066
- ISSN
0306-5251
- Publication type
Article
- DOI
10.1111/bcp.13998